A noted dermatopathologist, Dr. Willman joins the PathologyWatch team to continue delivering the highest-quality care to patients.
PathologyWatch, a full-service digital dermatopathology solution, welcomes Dr. Joseph Willman, MD, to its team of respected pathologists. Dr. Willman, a dermatopathologist with over two decades of experience, will utilize state-of-the-art digital pathology workflows to deliver optimal patient care to dermatology clinics.
A board-certified pathologist and dermatopathologist, Dr. Willman completed his residency at the University of Utah, his dermatopathology fellowship at the University of Colorado, and his molecular genetic pathology fellowship at the University of Michigan.
Dr. Willman’s connection to pathology began long before his career and training. His father was a pathologist, introducing him to the profession at a young age. Still, he expected to follow a different career path. As a student, he spent time working in emergency rooms and found surgery and internal medicine interesting. However, his third-year medical school pathology rotation cemented his interest in pathology, and he now sees digital pathology as the future of the field.
“I think the majority of anatomic pathology will be done digitally, as technology advances to digitize the slides, because it makes it so easy to collaborate, get opinions on cases and implement quality measures to get multiple people reviewing a single case,” Dr. Willman said. “It’s so much more convenient than shipping or using a courier to share glass slides, which is easily a 48-hour process by itself. PathologyWatch can secure expert opinions from people all over the country in a single afternoon, and that’s revolutionary.”
With 20 years of experience in dermatopathology, Dr. Willman brings extensive expertise to PathologyWatch. Most recently, he served as the director of a national reference laboratory and molecular diagnostics lab, where he worked extensively with quality systems and compliance and regulation. His experience and interest in lab operations will help as PathologyWatch builds a digital laboratory platform incorporating quality measures that aren’t possible in a physical laboratory.
“We are thrilled to have Dr. Willman joining our team, not just for the years of experience he has but also for his enthusiasm for the future and commitment to progress and innovation,” said Dan Lambert, CEO at PathologyWatch. “He will be of particular help in moving our molecular efforts forward.”